Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Clin Neuropharmacol. 2010 Mar–Apr;33(2):91–101. doi: 10.1097/WNF.0b013e3181cbf825

FIG. 3.

FIG. 3

Treatment with oral fingolimod prevents the egress of naïve and central memory T cells (TCM) from lymph nodes into the circulation but spares effector memory T cells (TEM). Percentages of naïve T cells, TCM and TEM cells in peripheral blood in patients with relapsing multiple sclerosis treated with fingolimod and in untreated patients. Adapted from Mehling et al. 2008 (72).

MS, multiple sclerosis; naïve, naïve T cells (CCR7+, CD45RA+); TCM cells, central memory T cells (CCR7+, CD45RA−); TEM cells, effector memory T cells (CCR7−, CD45RA−).